▲ Peaking
Business
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
Ionis-partnered ALS drug hits primary phase 3 endpoint
Ionis Pharmaceuticals
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Ionis Pharmaceuticals
This hub groups 3 separate news trends connected to Ionis Pharmaceuticals, spanning August 28, 2026 through September 22, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 18 article observations and 16 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
AstraZeneca and Ionis' failed heart disease trial raises questions about the future of RNA drugs
◼ Archived
Business
🔮 fades ✓
Alnylam’s heart drug troubles take center stage at a cardiology conference
AstraZeneca's failed heart disease drug trial casts doubt on a promising class of treatments